Pfizer (XSWX:PFE) Beginning Cash Position: CHF942 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PFE Pfizer Inc XSWX:PFE
69 GF Score
Price CHF19.81
GF Value CHF21.05
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Beginning Cash Position?

Pfizer XSWX:PFE +1.17% 69 Beginning Cash Position is CHF942 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 69/100 and a GF Value™ of CHF21.05 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Beginning Cash Position for the quarter that ended in Mar. 2026 was CHF942 Mil.

Pfizer's quarterly Beginning Cash Position declined from Sep. 2025 (CHF1,350 Mil) to Dec. 2025 (CHF1,111 Mil) and declined from Dec. 2025 (CHF1,111 Mil) to Mar. 2026 (CHF942 Mil).

Pfizer's annual Beginning Cash Position increased from Dec. 2023 (CHF406 Mil) to Dec. 2024 (CHF2,601 Mil) but then declined from Dec. 2024 (CHF2,601 Mil) to Dec. 2025 (CHF882 Mil).

Pfizer Beginning Cash Position Related Terms

Pfizer Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Pfizer's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Beginning Cash Position Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,679.90 1,847.36 405.59 2,600.80 882.17

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 977.26 1,203.54 1,350.19 1,110.88 942.40
XSWX:PFE
69GF Score
Pfizer Inc XSWX:PFE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of CHF942 Mil mean?
Pfizer (XSWX:PFE) has a Beginning Cash Position of CHF942 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Pfizer and its competitors.
Is Pfizer's Beginning Cash Position too high?
Pfizer's current Beginning Cash Position is CHF942 Mil. Overall, Pfizer has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Beginning Cash Position compare to GILD and BMY?
Pfizer's Beginning Cash Position of CHF942 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Pfizer and its competitors. Pfizer's current Beginning Cash Position is CHF942 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.05, compared to a current price of CHF19.81 — trading 5.9% below its estimated fair value. The current Beginning Cash Position is CHF942 Mil. Pfizer's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Beginning Cash Position is CHF942 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.81 is trading 5.9% below its estimated GF Value™ of CHF21.05. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Beginning Cash Position: CHF942 Mil
  • GF Value™: CHF21.05 vs. price of CHF19.81 (5.9% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
69GF Score

Get the complete analysis for XSWX:PFE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.81
Price
CHF21.05
GF Value